Molecular Clamp technology platform for vaccines against life

Vicebio is at the forefront of vaccine development, leveraging its proprietary Molecular Clamp technology to create innovative solutions for life-threatening respiratory viral infections. This technology, developed at The University of Queensland, stabilizes viral glycoproteins in their pre-fusion conformation, which is crucial for eliciting a robust immune response. By ensuring that these proteins maintain their optimal structure, the Molecular Clamp technology enhances the efficacy and manufacturability of vaccines, allowing for the production of ready-to-use, fully liquid formulations. This approach addresses significant challenges in vaccine development, such as long-term storage and convenient administration, making it a transformative advancement in the field.

The Molecular Clamp technology has been successfully applied to various respiratory viruses, including respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and even SARS-CoV-2. Vicebio's current focus includes advancing its bivalent RSV/hMPV vaccine candidate, VXB-241, through clinical trials, particularly targeting older adults who are at higher risk for severe respiratory infections. The company aims to develop multivalent vaccines that can provide broad protection against multiple pathogens, thereby addressing critical public health needs. With a strong leadership team and a commitment to innovation, Vicebio is poised to make significant contributions to global respiratory health.

United Kingdom

Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.

Vicebio

Company Details